KalVista Pharmaceuticals Q4 Earnings Call Highlights
Corroborated by 1 source from 1 publisher
globalhealth1d ago
TL;DR
According to finance.yahoo.com, key Points - KalVista's oral HAE therapy EKTERLY showed strong early commercial traction, reporting $35.4 million in Q4 and $49.1 million in net product revenue from launch through Dec.